Literature DB >> 9331099

Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

F Courjal1, M Cuny, J Simony-Lafontaine, G Louason, P Speiser, R Zeillinger, C Rodriguez, C Theillet.   

Abstract

DNA amplification is frequent in breast cancer and has been associated with specific clinicopathological parameters and/or worsened course of the disease. In the present work, we were interested in further defining the association linking the occurrence of DNA amplification to the emergence of specific breast tumor phenotype. To this aim, we studied by Southern blotting a total of 1875 breast tumor DNAs with 26 probes mapping at 15 distinct chromosomal localizations. Of the 26 loci tested, 11 loci showed elevated levels of amplification, 9 loci showed occasional and/or low level of DNA copy number increase, and 6 loci showed very rare or no variation. This allowed us to define six amplified domains mapping at 8p12, 8q24, 11q13, 12q13, 17q12, and 20q13.2, respectively. Over 60% of the tumors analyzed presented at least one amplification at one of these localizations. Amplifications often covered large regions of DNA and bore complex patterns involving coamplification of several colocalized markers. Statistical analysis revealed correlations associating DNA amplification with breast tumor phenotype, as well as sets of preferential coamplifications. Based on these correlations, we defined three subsets of breast cancer according to their patterns of DNA amplification. The first subset (group A) was organized around the amplifications at 11q13 and/or 8p12 and was predominantly composed of estrogen receptor-positive tumors and presented a large proportion of lobular cancers. The second subset (group B) was organized around the amplifications of ERBB2 and/or MYC. These tumors were mostly estrogen receptor-negative and of the ductal invasive type. The third subset (group C) corresponded to tumors in which no amplification was detected in the present screen. Tumors in this group were largely diploid and of low histopathological grading.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331099

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

Review 1.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

2.  End-sequence profiling: sequence-based analysis of aberrant genomes.

Authors:  Stanislav Volik; Shaying Zhao; Koei Chin; John H Brebner; David R Herndon; Quanzhou Tao; David Kowbel; Guiqing Huang; Anna Lapuk; Wen-Lin Kuo; Gregg Magrane; Pieter De Jong; Joe W Gray; Colin Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-04       Impact factor: 11.205

3.  FGFR1 expression and gene copy numbers in human lung cancer.

Authors:  Lukas H Kohler; Masoud Mireskandari; Thomas Knösel; Annelore Altendorf-Hofmann; Almut Kunze; Andreas Schmidt; Norbert Presselt; Yuan Chen; Iver Petersen
Journal:  Virchows Arch       Date:  2012-05-31       Impact factor: 4.064

Review 4.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

5.  Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis.

Authors:  X Meng; A Vander Ark; P Lee; G Hostetter; N A Bhowmick; L M Matrisian; B O Williams; C K Miranti; X Li
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

Review 6.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

7.  The unique expression and function of miR-424 in human placental trophoblasts.

Authors:  Jean-Francois Mouillet; Rogier B Donker; Takuya Mishima; Tina Cronqvist; Tianjiao Chu; Yoel Sadovsky
Journal:  Biol Reprod       Date:  2013-08-01       Impact factor: 4.285

8.  RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.

Authors:  Bruno Bockorny; Maria Rusan; Wankun Chen; Rachel G Liao; Yvonne Li; Federica Piccioni; Jun Wang; Li Tan; Aaron R Thorner; Tianxia Li; Yanxi Zhang; Changhong Miao; Therese Ovesen; Geoffrey I Shapiro; David J Kwiatkowski; Nathanael S Gray; Matthew Meyerson; Peter S Hammerman; Adam J Bass
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

9.  FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Authors:  Joshua Z Drago; Luigi Formisano; Carlos L Arteaga; Aditya Bardia; Dejan Juric; Andrzej Niemierko; Alberto Servetto; Seth A Wander; Laura M Spring; Neelima Vidula; Jerry Younger; Jeffrey Peppercorn; Megan Yuen; Giuliana Malvarosa; Dennis Sgroi; Steven J Isakoff; Beverly Moy; Leif W Ellisen; A John Iafrate
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

10.  C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis.

Authors:  Zhuo Chen; Lin-Jiang Tong; Bai-You Tang; Hong-Yan Liu; Xin Wang; Tao Zhang; Xian-Wen Cao; Yi Chen; Hong-Lin Li; Xu-Hong Qian; Yu-Fang Xu; Hua Xie; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2018-11-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.